Trending...
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific
- BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
More on Nyenta.com
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
More on Nyenta.com
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- Happi Coffee Launches with a Mission to Bring Freshness, Simplicity, and Intention to Your Daily Cup
- SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
- Local firm Launches QuickBooks Support to Help Small Businesses Streamline Finances and Boost Growth
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- PR Brand Marketing Inc. Awarded GSA Multiple Award Schedule Contract with Strategic Support from Government Marketplace LLC
- LG GUGGENHEIM AWARD WINNER AYOUNG KIM OFFERS SNEAK PEAK INTO HER WORK PROCESS
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Interview with Dr. Eboni Ivory Green About Her New Book - Journey Beyond the Yellow Brick Road
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Yama Industrials Announces Next-Generation Data Analytics Platform
- Container Gardening eBook Launches Free "Recipe Designer" to End Common Potting Soil Mistakes
- Emmy-Winning Journalist José Martínez Releases Debut Book Your English is Great, But…
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Groupon, Inc. - GRPN
- BuggerCoin Blasts Off on Pump.Fun Ahead of $4B $PUMP ICO
- DimHum Announces Innovative Crowdshipping for USA, UK, Canada
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: HSON, ENZB, and BRZH
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Momentum Commerce Tracking of Amazon US Prime Day Sales Shows +165% Increase on Day 3, Path to Year-over-Year Growth
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Olson's Walk-Off Hit Gives N.L. All-Star Game Triumph In Strat-O-Matic Simulation
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific